Investors News Releases Sign up for email alerts to receive company and investor updates News Releases Investor Relations Investor Relations News Releases Presentations & Events Common Stock Information Stock Quote & Chart Analyst Coverage SEC Filings Corporate Governance Overview Board of Directors Committee Composition Management Team Annual Reports News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Apr 08 2009 Cyclacel Pharmaceuticals announces suspension of quarterly dividend on 6% Convertible Exchangeable Preferred Stock Mar 31 2009 Cyclacel Pharmaceuticals announces Financial Results for Fourth Quarter and year ended December 31, 2008 Mar 24 2009 Cyclacel Pharmaceuticals to announce Fourth Quarter 2008 Financial Results on March 31, 2009 Mar 05 2009 Phase 1 data published elucidating pharmacodynamics & mechanism of action of seliciclib in nasopharyngeal cancer Feb 06 2009 Cyclacel Pharmaceuticals advances oral sapacitabine pivotal trial plan in hematological malignancies Feb 02 2009 Cyclacel Pharmaceuticals to present at BIO CEO & Investor Conference Jan 13 2009 Cyclacel begins Phase 2 study of oral sapacitabine in patients with previously treated non-small cell lung cancer Nov 07 2008 Cyclacel Pharmaceuticals to present at Rodman & Renshaw 10th Annual Healthcare Conference Nov 06 2008 Cyclacel Pharmaceuticals announces Third Quarter 2008 Financial Results Oct 31 2008 Cyclacel Pharmaceuticals to announce Third Quarter 2008 Financial Results on November 6, 2008 Oct 22 2008 Cyclacel Pharmaceuticals to present at BIO Investor Forum Oct 21 2008 Cyclacel to present preclinical data showing synergy of combination of sapacitabine with histone deacetylating agents Oct 09 2008 Cyclacel announces completion of enrollment in Phase 2 trial of sapacitabine in elderly AML Sep 16 2008 Cyclacel announces revised operating plan & refocused resources Sep 12 2008 Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS Sep 08 2008 Cyclacel appoints Nicholas Bacopoulos, Ph.D. to Board of Directors Aug 28 2008 CYCLACEL announces recommendations of data review committee for seliciclib Phase 2b non-small cell lung cancer APPRAISE trial Aug 07 2008 Cyclacel Pharmaceuticals announces second quarter 2008 financial results Aug 07 2008 Cyclacel Pharmaceuticals to present at the 28th Annual Canaccord Adams Global Growth Conference Jul 31 2008 Cyclacel Pharmaceuticals to announce Second Quarter 2008 Financial Results on August 7, 2008 Jul 14 2008 Cyclacel publishes study of seliciclib synergy with Tarceva and Herceptin in journal Clinical Cancer Research Jul 07 2008 XCLAIR® reported to be safe and effective in study published in European Journal of Dermatology Jul 02 2008 Cyclacel to present at Collins Stewart Fourth Annual Growth Conference Jun 06 2008 Cyclacel to present at Annual Needham Biotechnology & Medical Technology Conference May 29 2008 Vall d’Hebron University Hospital and Cyclacel to initiate Phase 1 combination study of Seliciclib and Tarceva® Pagination First page « first Previous page ‹ previous … Page 13 Page 14 Page 15 Page 16 Current page 17 Page 18 Page 19 Page 20 Page 21 Next page next › Last page last » Toolkit Email AlertsRSS FeedsPrint Page
News Releases Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Apr 08 2009 Cyclacel Pharmaceuticals announces suspension of quarterly dividend on 6% Convertible Exchangeable Preferred Stock Mar 31 2009 Cyclacel Pharmaceuticals announces Financial Results for Fourth Quarter and year ended December 31, 2008 Mar 24 2009 Cyclacel Pharmaceuticals to announce Fourth Quarter 2008 Financial Results on March 31, 2009 Mar 05 2009 Phase 1 data published elucidating pharmacodynamics & mechanism of action of seliciclib in nasopharyngeal cancer Feb 06 2009 Cyclacel Pharmaceuticals advances oral sapacitabine pivotal trial plan in hematological malignancies Feb 02 2009 Cyclacel Pharmaceuticals to present at BIO CEO & Investor Conference Jan 13 2009 Cyclacel begins Phase 2 study of oral sapacitabine in patients with previously treated non-small cell lung cancer Nov 07 2008 Cyclacel Pharmaceuticals to present at Rodman & Renshaw 10th Annual Healthcare Conference Nov 06 2008 Cyclacel Pharmaceuticals announces Third Quarter 2008 Financial Results Oct 31 2008 Cyclacel Pharmaceuticals to announce Third Quarter 2008 Financial Results on November 6, 2008 Oct 22 2008 Cyclacel Pharmaceuticals to present at BIO Investor Forum Oct 21 2008 Cyclacel to present preclinical data showing synergy of combination of sapacitabine with histone deacetylating agents Oct 09 2008 Cyclacel announces completion of enrollment in Phase 2 trial of sapacitabine in elderly AML Sep 16 2008 Cyclacel announces revised operating plan & refocused resources Sep 12 2008 Cyclacel expands Phase 2 sapacitabine trial in elderly AML to include patients with MDS Sep 08 2008 Cyclacel appoints Nicholas Bacopoulos, Ph.D. to Board of Directors Aug 28 2008 CYCLACEL announces recommendations of data review committee for seliciclib Phase 2b non-small cell lung cancer APPRAISE trial Aug 07 2008 Cyclacel Pharmaceuticals announces second quarter 2008 financial results Aug 07 2008 Cyclacel Pharmaceuticals to present at the 28th Annual Canaccord Adams Global Growth Conference Jul 31 2008 Cyclacel Pharmaceuticals to announce Second Quarter 2008 Financial Results on August 7, 2008 Jul 14 2008 Cyclacel publishes study of seliciclib synergy with Tarceva and Herceptin in journal Clinical Cancer Research Jul 07 2008 XCLAIR® reported to be safe and effective in study published in European Journal of Dermatology Jul 02 2008 Cyclacel to present at Collins Stewart Fourth Annual Growth Conference Jun 06 2008 Cyclacel to present at Annual Needham Biotechnology & Medical Technology Conference May 29 2008 Vall d’Hebron University Hospital and Cyclacel to initiate Phase 1 combination study of Seliciclib and Tarceva® Pagination First page « first Previous page ‹ previous … Page 13 Page 14 Page 15 Page 16 Current page 17 Page 18 Page 19 Page 20 Page 21 Next page next › Last page last »
Apr 08 2009 Cyclacel Pharmaceuticals announces suspension of quarterly dividend on 6% Convertible Exchangeable Preferred Stock
Mar 31 2009 Cyclacel Pharmaceuticals announces Financial Results for Fourth Quarter and year ended December 31, 2008
Mar 24 2009 Cyclacel Pharmaceuticals to announce Fourth Quarter 2008 Financial Results on March 31, 2009
Mar 05 2009 Phase 1 data published elucidating pharmacodynamics & mechanism of action of seliciclib in nasopharyngeal cancer
Feb 06 2009 Cyclacel Pharmaceuticals advances oral sapacitabine pivotal trial plan in hematological malignancies
Jan 13 2009 Cyclacel begins Phase 2 study of oral sapacitabine in patients with previously treated non-small cell lung cancer
Nov 07 2008 Cyclacel Pharmaceuticals to present at Rodman & Renshaw 10th Annual Healthcare Conference
Oct 31 2008 Cyclacel Pharmaceuticals to announce Third Quarter 2008 Financial Results on November 6, 2008
Oct 21 2008 Cyclacel to present preclinical data showing synergy of combination of sapacitabine with histone deacetylating agents
Oct 09 2008 Cyclacel announces completion of enrollment in Phase 2 trial of sapacitabine in elderly AML
Aug 28 2008 CYCLACEL announces recommendations of data review committee for seliciclib Phase 2b non-small cell lung cancer APPRAISE trial
Aug 07 2008 Cyclacel Pharmaceuticals to present at the 28th Annual Canaccord Adams Global Growth Conference
Jul 31 2008 Cyclacel Pharmaceuticals to announce Second Quarter 2008 Financial Results on August 7, 2008
Jul 14 2008 Cyclacel publishes study of seliciclib synergy with Tarceva and Herceptin in journal Clinical Cancer Research
Jul 07 2008 XCLAIR® reported to be safe and effective in study published in European Journal of Dermatology
May 29 2008 Vall d’Hebron University Hospital and Cyclacel to initiate Phase 1 combination study of Seliciclib and Tarceva®
